Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
31.49 (1y: +1%)
Market Cap 1.84 B P/E(ttm) 38.30
Enterprise Value 1.66 B P/B 3.00
THOR- NAS (USA)
Thoratec Corporation
  • Currently 3/5
Business Predictability Rank: 3-Star (On Watch)
Back Testing Results:
Average gain of all 3-Star stocks: 8.2% per year.
% of Stocks that are in still loss if held for 10yrs: 11%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$31.49
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry		 vs
history
Cash to Debt 59.182
THOR's Cash to Debt is ranked higher than
89% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 3750.67 vs. THOR: 59.182 )
THOR' s 10-Year Cash to Debt Range
Min: 1.04   Max: No Debt
Current: 59.18
Equity to Asset 0.528
THOR's Equity to Asset is ranked lower than
53% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 0.53 vs. THOR: 0.528 )
THOR' s 10-Year Equity to Asset Range
Min: 0.09   Max: 0.81
Current: 0.53
0.09
0.81
Interest Coverage No Debt
THOR's Interest Coverage is ranked higher than
90% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 420.30 vs. THOR: No Debt )
THOR' s 10-Year Interest Coverage Range
Min: 8   Max: No Debt
Current: No Debt
F-Score: 5
Z-Score: 14.21
M-Score: -2.86
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry		 vs
history
Operating margin (%) 15.40
THOR's Operating margin (%) is ranked higher than
96% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 5.80 vs. THOR: 15.40 )
THOR' s 10-Year Operating margin (%) Range
Min: -82.5   Max: 27
Current: 15.4
-82.5
27
Net-margin (%) 11.4
THOR's Net-margin (%) is ranked higher than
93% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 3.25 vs. THOR: 11.4 )
THOR' s 10-Year Net-margin (%) Range
Min: -77.5   Max: 16.9
Current: 11.4
-77.5
16.9
ROE (%) 9.4
THOR's ROE (%) is ranked higher than
82% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 4.80 vs. THOR: 9.4 )
THOR' s 10-Year ROE (%) Range
Min: -23.5   Max: 12.2
Current: 9.4
-23.5
12.2
ROA (%) 8
THOR's ROA (%) is ranked higher than
87% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 3.40 vs. THOR: 8 )
THOR' s 10-Year ROA (%) Range
Min: -16.6   Max: 10.5
Current: 8
-16.6
10.5
ROC (Joel Greenblatt) (%) 58.80
THOR's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 14.00 vs. THOR: 58.80 )
THOR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -140   Max: 81.8
Current: 58.8
-140
81.8
Revenue Growth (%) 6.1
THOR's Revenue Growth (%) is ranked higher than
81% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. THOR: 6.1 )
THOR' s 10-Year Revenue Growth (%) Range
Min: 5.8   Max: 20.4
Current: 6.1
5.8
20.4
EBITDA Growth (%) 7.5
THOR's EBITDA Growth (%) is ranked higher than
92% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: -1.10 vs. THOR: 7.5 )
THOR' s 10-Year EBITDA Growth (%) Range
Min: -4.7   Max: 51.5
Current: 7.5
-4.7
51.5
EPS Growth (%) 17.7
THOR's EPS Growth (%) is ranked higher than
95% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 2.10 vs. THOR: 17.7 )
THOR' s 10-Year EPS Growth (%) Range
Min: -15.9   Max: 125.8
Current: 17.7
-15.9
125.8
ยป THOR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

THOR Guru Trades in Q2 2012

Paul Tudor Jones 8,300 sh (New)
Joel Greenblatt 90,834 sh (+122.67%)
Daniel Loeb 1,000,000 sh (+100%)
Jim Simons 1,040,939 sh (+76.42%)
Chuck Royce 1,440,500 sh (+25.15%)
Manning & Napier Advisors, Inc 358,640 sh (-0.57%)
John Burbank 648,336 sh (-41.93%)
Steven Cohen 16,359 sh (-71.93%)
» More
Q3 2012

THOR Guru Trades in Q3 2012

Manning & Napier Advisors, Inc 364,140 sh (+1.53%)
Daniel Loeb Sold Out
Paul Tudor Jones Sold Out
Jim Simons Sold Out
Joel Greenblatt 72,252 sh (-20.46%)
Steven Cohen 12,255 sh (-25.09%)
Chuck Royce 1,047,200 sh (-27.3%)
John Burbank 400,180 sh (-38.28%)
» More
Q4 2012

THOR Guru Trades in Q4 2012

Steven Cohen 26,770 sh (+118.44%)
Manning & Napier Advisors, Inc 370,940 sh (+1.87%)
John Burbank 400,000 sh (-0.04%)
Joel Greenblatt 70,833 sh (-1.96%)
Chuck Royce 969,900 sh (-7.38%)
» More
Q1 2013

THOR Guru Trades in Q1 2013

Paul Tudor Jones 8,800 sh (New)
Jim Simons 1,579,239 sh (New)
Joel Greenblatt 109,834 sh (+55.06%)
Manning & Napier Advisors, Inc 376,410 sh (+1.47%)
Chuck Royce 841,900 sh (-13.2%)
John Burbank 225,000 sh (-43.75%)
Steven Cohen 8,831 sh (-67.01%)
» More
» Details

Insider Trades

Latest Guru Trades with THOR

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2013-03-31 Reduce -43.75%0.25%$35.22 - $38.12 $ 31.49-13%225000
Joel Greenblatt 2013-03-31 Add 55.06%0.07%$35.22 - $38.12 $ 31.49-13%109834
Daniel Loeb 2012-09-30 Sold Out 1%$31.17 - $36.03 $ 31.49-7%0
John Burbank 2012-09-30 Reduce -38.28%0.28%$31.17 - $36.03 $ 31.49-7%400180
Joel Greenblatt 2012-09-30 Reduce -20.46%0.05%$31.17 - $36.03 $ 31.49-7%72252
John Burbank 2012-06-30 Reduce -41.93%0.55%$29.75 - $35.87 $ 31.49-3%648336
Daniel Loeb 2012-06-30 Add 100%0.5%$29.75 - $35.87 $ 31.49-3%1000000
Joel Greenblatt 2012-06-30 Add 122.67%0.12%$29.75 - $35.87 $ 31.49-3%90834
John Burbank 2012-03-31 Reduce -44.49%2.4%$29 - $35.72 $ 31.492%1116400
Daniel Loeb 2012-03-31 New Buy0.42%$29 - $35.72 $ 31.492%500000
Joel Greenblatt 2012-03-31 Add 72.67%0.05%$29 - $35.72 $ 31.492%40793
Joel Greenblatt 2011-12-31 Add 52.64%0.03%$28.16 - $37.37 $ 31.49-2%23625
George Soros 2011-12-31 Sold Out 0.0002%$28.16 - $37.37 $ 31.49-2%0
Lee Ainslie 2011-09-30 Sold Out 0.5256%$30.16 - $36.64 $ 31.49-5%0
Joel Greenblatt 2011-09-30 Reduce -32.52%0.03%$30.16 - $36.64 $ 31.49-5%15478
George Soros 2011-09-30 New Buy$30.16 - $36.64 $ 31.49-5%400
Lee Ainslie 2011-06-30 Reduce -68.97%1.01%$26.42 - $35.7 $ 31.490%1661138
Joel Greenblatt 2011-06-30 Reduce -33.02%0.09%$26.42 - $35.7 $ 31.490%22936
Lee Ainslie 2011-03-31 Add 168.61%0.92%$23.06 - $31.2 $ 31.4916%5353060
Joel Greenblatt 2011-03-31 Add 55.11%0.1%$23.06 - $31.2 $ 31.4916%34241
Lee Ainslie 2010-12-31 New Buy0.6%$24.74 - $37.26 $ 31.494%1992854
Joel Greenblatt 2010-12-31 New Buy0.2%$24.74 - $37.26 $ 31.494%22076
George Soros 2010-12-31 Sold Out 0.06%$24.74 - $37.26 $ 31.494%0
George Soros 2010-09-30 New Buy0.06%$32.2 - $44.97 $ 31.49-18%100000
Premium More recent guru trades are included for Premium Members only!!

Ratios

vs
industry		 vs
history
P/E(ttm) 38.30
THOR's P/E(ttm) is ranked higher than
68% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 24.10 vs. THOR: 38.30 )
THOR' s 10-Year P/E(ttm) Range
Min: 22.61   Max: 940
Current: 38.3
22.61
940
P/B 3.00
THOR's P/B is ranked lower than
65% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 1.99 vs. THOR: 3.00 )
THOR' s 10-Year P/B Range
Min: 0.86   Max: 19.77
Current: 3
0.86
19.77
P/S 3.87
THOR's P/S is ranked lower than
82% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. THOR: 3.87 )
THOR' s 10-Year P/S Range
Min: 2.61   Max: 16.18
Current: 3.87
2.61
16.18
PFCF 19.30
THOR's PFCF is ranked higher than
65% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 18.60 vs. THOR: 19.30 )
THOR' s 10-Year PFCF Range
Min: 8.47   Max: 2111
Current: 19.3
8.47
2111
EV-to-EBIT 26.3
THOR's EV-to-EBIT is ranked higher than
72% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 16.25 vs. THOR: 26.3 )
THOR' s 10-Year EV-to-EBIT Range
Min: 10.4   Max: 287.2
Current: 26.3
10.4
287.2
PEG 1.7
THOR's PEG is ranked higher than
99% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 1.23 vs. THOR: 1.7 )
THOR' s 10-Year PEG Range
Min: 0.43   Max: 290.14
Current: 1.7
0.43
290.14
Shiller P/E 42.1
THOR's Shiller P/E is ranked higher than
79% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 23.60 vs. THOR: 42.1 )
THOR' s 10-Year Shiller P/E Range
Min: 42.1   Max: 427.2
Current: 42.1
42.1
427.2

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 12.2
THOR's Price/Net Cash is ranked higher than
88% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 12.00 vs. THOR: 12.2 )
THOR' s 10-Year Price/Net Cash Range
Min: 7.2   Max: 363.8
Current: 12.2
7.2
363.8
Price/Net Current Asset Value 20.7
THOR's Price/Net Current Asset Value is ranked higher than
88% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 8.90 vs. THOR: 20.7 )
THOR' s 10-Year Price/Net Current Asset Value Range
Min: 11.1   Max: 27.9
Current: 20.7
11.1
27.9
Price/Tangible Book 4.9
THOR's Price/Tangible Book is ranked higher than
79% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 3.80 vs. THOR: 4.9 )
THOR' s 10-Year Price/Tangible Book Range
Min: 3.8   Max: 12.4
Current: 4.9
3.8
12.4
Price/DCF (Projected) 1.4
THOR's Price/DCF (Projected) is ranked higher than
86% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 1.25 vs. THOR: 1.4 )
THOR' s 10-Year Price/DCF (Projected) Range
Min: 1.8   Max: 3.6
Current: 1.4
1.8
3.6
Price/Median PS Value 0.8
THOR's Price/Median PS Value is ranked higher than
82% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 0.80 vs. THOR: 0.8 )
THOR' s 10-Year Price/Median PS Value Range
Min: 0.7   Max: 1.8
Current: 0.8
0.7
1.8
Price/Peter Lynch Fair Value 1.5
THOR's Price/Peter Lynch Fair Value is ranked higher than
95% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 2.10 vs. THOR: 1.5 )
THOR' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1.1   Max: 26
Current: 1.5
1.1
26
Price/Graham Number 2.7
THOR's Price/Graham Number is ranked higher than
83% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 1.80 vs. THOR: 2.7 )
THOR' s 10-Year Price/Graham Number Range
Min: 2.2   Max: 10.5
Current: 2.7
2.2
10.5
Earnings Yield (Greenblatt) 3.80
THOR's Earnings Yield (Greenblatt) is ranked higher than
83% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 5.95 vs. THOR: 3.80 )
THOR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 9.6
Current: 3.8
0.3
9.6
Forward Rate of Return (Yacktman) 31.55
THOR's Forward Rate of Return (Yacktman) is ranked higher than
90% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 3.03 vs. THOR: 31.55 )
THOR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -16.4   Max: 57.9
Current: 31.55
-16.4
57.9

Business Description

Thoratec Corporation incorporated in the State of California in 1976 provides mechanical circulatory support with a product portfolio to treat the full range of clinical needs for advanced heart failure patients. It develops, manufactures and markets proprietary medical devices used for circulatory support. Following the sale of ITC in 2010, the Company has one operating segment: Cardiovascular group. This segment is organized and operates to develop and manufacture mechanical circulatory products to support the cardiovascular systems of humans. The Company's VAD products primarily serve patients suffering from late-stage HF. HF is a chronic disease that occurs when degeneration of the heart muscle reduces the pumping power of the heart, causing the heart to become too weak to pump blood at a level sufficient to meet the body's demands. Hospitals that perform open heart surgery and heart transplants are the potential customers for its Thoratec and HeartMate products. The Company estimates that it sells into 293 of these centers. According to the Company's estimates, it is in approximately 149 centers in the United States and 144 centers internationally. Competition from medical device companies and medical device divisions of healthcare companies, pharmaceutical companies and gene- and cell-based therapies is intense and is expected to increase. It therefore continues to expect new competitors both from the pharmacological and the medical device space. Among the medical device competitors are Terumo Heart, Inc., HeartWare International Inc., AbioMed, Inc., Jarvik Heart, Inc., MicroMed Technology, Inc., SynCardia Systems, Inc., CirculLite, Aachen Innovative Solutions GmbH, and WorldHeart Corporation in the U.S. and Europe and Berlin Heart GmbH in Europe. All of the Company's proposed products will require regulatory approval prior to commercialization. In particular, medical devices are subject to rigorous pre-clinical testing as a condition of approval by the FDA and by similar authorities in foreign countries.
Company Website
SEC Reports
Industry: Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ
Traded in other countries:TL1.Germany
ยป More Articles for THOR

Headlines

Articles On GuruFocus.com
Royce Fund's Chip Skinner on the Rebound of Royce Value Plus Fund and Stock Ideas Dec 04 2012 
5 Strong Healthcare Stocks For 2012 Mar 24 2012 
Consider These 5 Healthcare Stocks Now Mar 21 2012 
Weekly Guru Bargains Highlights: CSTR, VRX, SAY, THOR, BVN Feb 12 2011 
Weekly Guru Bargains Highlights: SVU, MSI, THOR, JNY, AMLN Jan 23 2011 
Weekly Guru Bargains Highlights: SAY, STRA, SVU, THOR, VRX Jan 15 2011 
Weekly Guru Bargains Highlights: SAY, VRX, THOR, SVU, NUVA Jan 09 2011 
Weekly Guru Bargains Highlights: DF, CLWR, THOR, VRX, ASIA Dec 26 2010 
Weekly Guru Bargains Highlights: TFSL, THOR, CISG, VRX, DLR Dec 18 2010 
Weekly Guru Bargains Highlights: THOR, SKX, AMLN, SAY, JOE Dec 12 2010 

More From Our Partners
FDA Nod for Thoratec Controller - Analyst Blog May 20 2013 - ZACKS

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial